Randomised Phase 1 clinical trials in oncology

Area of Science:

• Oncology
• Clinical Trial Design
• Drug Development

Background:

• Phase 1 oncology trials have evolved beyond solely assessing tolerability.
• Current early-phase trials aim to gather robust evidence for clinical activity.
• This is crucial for expedited drug approvals like Accelerated Approval or Breakthrough Therapy designations.

Purpose of the Study:

• To outline the expanded objectives of modern Phase 1 oncology trials.
• To discuss the complexities and considerations in designing these multi-objective trials.
• To emphasize adherence to ethical and scientific principles in early-phase research.

Main Methods:

• The article reviews the evolving landscape of Phase 1 oncology trial objectives.
• It discusses the challenges in incorporating multiple endpoints and randomization.
• Considerations for trial design that maximize information and minimize bias are outlined.

Main Results:

• Phase 1 trials increasingly incorporate goals of demonstrating clinical activity.
• Designing trials to meet multiple objectives, including potential for accelerated approval, is complex.
• Effective design is essential for generating compelling data from early-phase studies.

Conclusions:

• The scope of Phase 1 oncology trials has significantly broadened.
• Thoughtful trial design is imperative to address multiple objectives, ensure ethical conduct, and generate robust evidence for drug approval pathways.
• Adherence to scientific and ethical principles is paramount in early-phase clinical research.